Resmed Inc. (RMD)

$252.86

+3.3

(+1.32%)▲

Market is closed - opens 7 PM, 11 Sep 2024

Performance

  • $247.41
    $253.10
    $252.86
    downward going graph

    2.16%

    Downside

    Day's Volatility :2.25%

    Upside

    0.09%

    downward going graph
  • $132.24
    $252.86
    $252.86
    downward going graph

    47.7%

    Downside

    52 Weeks Volatility :47.7%

    Upside

    0.0%

    downward going graph

Returns

PeriodResmed Inc.Sector (Health Care)S&P500
3 Months
15.69%
4.7%
2.1%
6 Months
29.05%
5.1%
6.8%
1 Year
61.62%
16.6%
22.7%
3 Years
-17.16%
15.6%
22.7%

Highlights

Market Capitalization
36.0B
Book Value
$33.11
Dividend Share
1.92
Dividend Yield
0.87%
Earnings Per Share (EPS)
6.93
PE Ratio
35.33
PEG Ratio
2.05
Wall Street Target Price
226.9
Profit Margin
21.79%
Operating Margin TTM
31.17%
Return On Assets TTM
12.7%
Return On Equity TTM
22.7%
Revenue TTM
4.7B
Revenue Per Share TTM
31.87
Quarterly Revenue Growth YOY
9.0%
Gross Profit TTM
2.4B
EBITDA
1.5B
Diluted Eps TTM
6.93
Quarterly Earnings Growth YOY
0.27
EPS Estimate Current Year
7.71
EPS Estimate Next Year
8.63
EPS Estimate Current Quarter
2.07
EPS Estimate Next Quarter
2.0

Analyst Recommendation

Buy
    63%Buy
    36%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Resmed Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
7
7
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 10.27%

Current $252.86
Target $226.90

Company Financials

FY19Y/Y Change
Revenue
2.6B
↑ 11.38%
Net Income
404.6M
↑ 28.2%
Net Profit Margin
15.52%
↑ 2.03%
FY20Y/Y Change
Revenue
3.0B
↑ 13.44%
Net Income
621.7M
↑ 53.65%
Net Profit Margin
21.02%
↑ 5.5%
FY21Y/Y Change
Revenue
3.2B
↑ 8.11%
Net Income
474.5M
↓ 23.67%
Net Profit Margin
14.84%
↓ 6.18%
FY22Y/Y Change
Revenue
3.6B
↑ 11.93%
Net Income
779.4M
↑ 64.26%
Net Profit Margin
21.78%
↑ 6.94%
FY23Y/Y Change
Revenue
4.2B
↑ 18.02%
Net Income
897.6M
↑ 15.15%
Net Profit Margin
21.25%
↓ 0.53%
FY24Y/Y Change
Revenue
4.7B
↑ 10.95%
Net Income
1.0B
↑ 13.75%
Net Profit Margin
21.79%
↑ 0.54%
Q1 FY23Q/Q Change
Revenue
1.1B
↑ 8.04%
Net Income
232.5M
↑ 3.37%
Net Profit Margin
20.82%
↓ 0.94%
Q2 FY23Q/Q Change
Revenue
1.1B
↑ 0.46%
Net Income
229.7M
↓ 1.22%
Net Profit Margin
20.47%
↓ 0.35%
Q3 FY23Q/Q Change
Revenue
963.0M
↓ 14.17%
Net Income
219.4M
↓ 4.46%
Net Profit Margin
22.78%
↑ 2.31%
Q4 FY23Q/Q Change
Revenue
1.2B
↑ 20.74%
Net Income
208.8M
↓ 4.84%
Net Profit Margin
17.96%
↓ 4.82%
Q1 FY24Q/Q Change
Revenue
1.2B
↑ 2.94%
Net Income
300.5M
↑ 43.91%
Net Profit Margin
25.1%
↑ 7.14%
Q2 FY24Q/Q Change
Revenue
1.2B
↑ 2.19%
Net Income
292.2M
↓ 2.75%
Net Profit Margin
23.89%
↓ 1.21%
FY19Y/Y Change
Total Assets
4.1B
↑ 34.07%
Total Liabilities
2.0B
↑ 102.55%
FY20Y/Y Change
Total Assets
4.6B
↑ 11.68%
Total Liabilities
2.1B
↑ 2.7%
FY21Y/Y Change
Total Assets
4.7B
↑ 3.07%
Total Liabilities
1.8B
↓ 11.86%
FY22Y/Y Change
Total Assets
5.1B
↑ 7.78%
Total Liabilities
1.7B
↓ 5.83%
FY23Y/Y Change
Total Assets
6.8B
↑ 32.49%
Total Liabilities
2.6B
↑ 51.1%
FY24Y/Y Change
Total Assets
6.9B
↑ 1.79%
Total Liabilities
2.0B
↓ 23.4%
Q1 FY23Q/Q Change
Total Assets
6.7B
↑ 0.57%
Total Liabilities
2.8B
↓ 5.33%
Q2 FY23Q/Q Change
Total Assets
6.8B
↑ 0.56%
Total Liabilities
2.6B
↓ 5.74%
Q3 FY23Q/Q Change
Total Assets
6.7B
↓ 0.16%
Total Liabilities
2.5B
↓ 5.01%
Q4 FY23Q/Q Change
Total Assets
6.9B
↑ 2.44%
Total Liabilities
2.4B
↓ 2.7%
Q1 FY24Q/Q Change
Total Assets
6.8B
↓ 1.31%
Total Liabilities
2.2B
↓ 9.85%
Q2 FY24Q/Q Change
Total Assets
6.9B
↑ 0.85%
Total Liabilities
2.0B
↓ 8.07%
FY19Y/Y Change
Operating Cash Flow
459.1M
↓ 9.1%
Investing Cash Flow
-1.1B
↑ 956.44%
Financing Cash Flow
580.6M
↓ 156.55%
FY20Y/Y Change
Operating Cash Flow
802.3M
↑ 74.76%
Investing Cash Flow
-179.9M
↓ 83.28%
Financing Cash Flow
-317.3M
↓ 154.64%
FY21Y/Y Change
Operating Cash Flow
736.7M
↓ 8.17%
Investing Cash Flow
-158.5M
↓ 11.9%
Financing Cash Flow
-764.6M
↑ 140.99%
FY22Y/Y Change
Operating Cash Flow
351.1M
↓ 52.34%
Investing Cash Flow
-229.9M
↑ 45.09%
Financing Cash Flow
-128.4M
↓ 83.21%
FY23Y/Y Change
Operating Cash Flow
693.3M
↑ 97.44%
Investing Cash Flow
-1.2B
↑ 404.46%
Financing Cash Flow
422.9M
↓ 429.44%
Q1 FY23Q/Q Change
Operating Cash Flow
282.6M
↑ 119.66%
Investing Cash Flow
-28.1M
↓ 97.26%
Financing Cash Flow
-279.6M
↓ 129.97%
Q2 FY23Q/Q Change
Operating Cash Flow
237.4M
↓ 15.97%
Investing Cash Flow
-1.2B
↑ 4026.97%
Financing Cash Flow
-188.6M
↓ 32.54%
Q3 FY23Q/Q Change
Operating Cash Flow
286.3M
↑ 20.57%
Investing Cash Flow
-149.0M
↓ 87.16%
Financing Cash Flow
-151.1M
↓ 19.86%

Technicals Summary

Sell

Neutral

Buy

Resmed Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Resmed Inc.
Resmed Inc.
14.08%
29.05%
61.62%
-17.16%
82.25%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
1.35%
24.52%
56.05%
38.3%
181.8%
Becton, Dickinson And Company
Becton, Dickinson And Company
-0.62%
-2.85%
-12.92%
-9.93%
-10.69%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
2.3%
-16.86%
-25.16%
-35.25%
110.72%
Alcon Ag
Alcon Ag
3.85%
7.39%
13.73%
12.96%
57.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Resmed Inc.
Resmed Inc.
35.33
35.33
2.05
7.71
0.23
0.13
0.01
33.11
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
81.91
81.91
4.06
6.65
0.16
0.08
NA
41.4
Becton, Dickinson And Company
Becton, Dickinson And Company
46.72
46.72
1.08
13.11
0.06
0.03
0.02
89.5
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.71
42.71
5.15
6.51
0.2
0.11
0.0
35.49
Alcon Ag
Alcon Ag
42.64
42.64
3.53
3.05
0.05
0.03
0.0
42.35
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Resmed Inc.
Resmed Inc.
Buy
$36.0B
82.25%
35.33
21.79%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$169.4B
181.8%
81.91
27.65%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.4B
-10.69%
46.72
7.13%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$21.8B
110.72%
42.71
18.25%
Alcon Ag
Alcon Ag
Buy
$46.7B
57.27%
42.64
11.44%

Insights on Resmed Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 963.03M → 1.22B (in $), with an average increase of 7.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 300.49M → 292.23M (in $), with an average decrease of 2.8% per quarter

Institutional Holdings

  • Vanguard Group Inc

    12.18%

  • BlackRock Inc

    7.96%

  • State Street Corporation

    4.29%

  • Bank of New York Mellon Corp

    3.93%

  • Geode Capital Management, LLC

    2.33%

  • Morgan Stanley - Brokerage Accounts

    1.32%

Corporate Announcements

  • Resmed Inc. Dividends March,2024

    In the quarter ending March,2024. Resmed Inc. has declared dividend of $0.48

    Read More

Company Information

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Organization
Resmed Inc.
Employees
9980
CEO
Mr. Michael J. Farrell BE, MBA, SM
Industry
Health Technology

Discover More

FAQs